WASHINGTON — May 5, 2026 — Hormonaly.ai™, a clinical research intelligence platform purpose-built for metabolic, anabolic, and longevity medicine, today announced the opening of its Evidence API to enterprise buyers — clinic networks, health platforms, and compounding pharmacies — as FDA regulatory pressure continues to reshape the peptide compounding market.
The platform, which has trained more than 1,000 clinicians and supports 17+ design-partner clinics, now offers white-label access to its GRADE-rated evidence synthesis engine. The API delivers structured, citation-backed clinical intelligence for peptide, hormone, and longevity medicine protocols — enabling operators to embed evidence-graded recommendations into their own digital workflows.
“Saying ‘I don’t know’ with confidence is a feature, not a failure,” said Fady Hannah-Shmouni, MD FRCPC, Founder of Hormonaly.ai. “Our evidence corpus is built to acknowledge uncertainty in the data so clinicians can make informed, defensible decisions.”
The corpus is reviewed by a clinical advisory board led by Fady Hannah-Shmouni, MD FRCPC, a board-certified endocrinologist formerly a principal investigator at the National Institutes of Health (NICHD). The platform’s 594+ protocols and 10,000+ citations are GRADE-rated and PubMed-verified, with a 99.9% SLA and full bilingual English/Arabic support for enterprise deployments.
Hormonaly.ai is a member of the NVIDIA Inception Program and Google Cloud for Startups, and is backed by FHS Capital.
About Hormonaly.ai
Hormonaly.ai is the Evidence OS for modern medicine — a clinical AI platform providing evidence-graded intelligence for peptide, hormone, and longevity medicine. The platform serves solo practitioners, multi-provider clinics, compounding pharmacies, and enterprise health networks. Learn more at hormonaly.ai.
Source: Business Wire, May 5, 2026
